Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assiut University
• Treatments: Ranibizumab; Triamcinolone

Criteria

Inclusion Criteria:

• Patients 18 years of age or older with visual impairment resulting from macular edema secondary to CRVO.

• A BCVA approximate Snellen equivalents, 20/40.

Exclusion Criteria:

• Use of intra-vitreal anti-VEGF injections 3 months or less before baseline.

• Pan-retinal laser photocoagulation 3 months or less before baseline,

• Topical ocular or systemic corticosteroids administered for 30 consecutive days.

• Intraocular or periocular corticosteroid use 3 months or less before screening (study eye),

• Use of intraocular corticosteroid implants,

• Uncontrolled glaucoma (intraocular pressure [IOP] 30 mmHg with medication) at the time of screening or baseline,

• iris neovascularization or neo-vascular glaucoma.